Update Alert 2: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.
作者信息
Hernandez Adrian V, Roman Yuani M, Pasupuleti Vinay, Barboza Joshuan J, White C Michael
机构信息
University of Connecticut Health Outcomes, Policy, and Evidence Synthesis Group and Hartford Hospital Department of Research Administration, Hartford, Connecticut, School of Pharmacy, Storrs, Connecticut, and Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru (A.V.H.).
University of Connecticut Health Outcomes, Policy, and Evidence Synthesis Group and Hartford Hospital Department of Research Administration, Hartford, Connecticut (Y.M.R.).
出版信息
Ann Intern Med. 2020 Oct 6;173(7):W128-W129. doi: 10.7326/L20-1054. Epub 2020 Aug 27.
Abstract
摘要
相似文献
1
Update Alert 2: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.更新警报2：羟氯喹或氯喹用于治疗或预防新型冠状病毒肺炎
Ann Intern Med. 2020 Oct 6;173(7):W128-W129. doi: 10.7326/L20-1054. Epub 2020 Aug 27.
2
Update Alert: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.最新警报：羟氯喹啉或氯喹啉用于治疗或预防2019冠状病毒病
Ann Intern Med. 2020 Aug 18;173(4):W78-W79. doi: 10.7326/L20-0945. Epub 2020 Jul 15.
3
Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians.最新警报2：临床医生应单独使用氯喹或羟氯喹，还是与阿奇霉素联合使用来预防或治疗新型冠状病毒肺炎？美国医师协会的临床实践要点
Ann Intern Med. 2020 Sep 1;173(5):W88-W89. doi: 10.7326/L20-1007. Epub 2020 Jul 30.
4
Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians.最新警报：临床医生应单独使用氯喹或羟氯喹，还是与阿奇霉素联合使用来预防或治疗新型冠状病毒肺炎？美国医师协会的实践要点
Ann Intern Med. 2020 Jul 21;173(2):W48-W51. doi: 10.7326/M20-3862. Epub 2020 Jun 17.
5
Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19).关于氯喹/羟氯喹治疗 2019 年冠状病毒病（COVID-19）的最新情况。
Biosci Trends. 2020 May 21;14(2):156-158. doi: 10.5582/bst.2020.03072. Epub 2020 Apr 13.
6
Could Chloroquine /Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment?氯喹/羟氯喹在2019冠状病毒病（COVID-19）治疗中会有害吗？
Clin Infect Dis. 2020 Jul 28;71(15):888-889. doi: 10.1093/cid/ciaa321.
7
Update Alert 3: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.最新警报3：羟氯喹或氯喹用于治疗或预防新型冠状病毒肺炎
Ann Intern Med. 2020 Dec 1;173(11):W156-W157. doi: 10.7326/L20-1257. Epub 2020 Oct 21.
8
Chloroquine and Hydroxychloroquine in COVID-19: Challenges and the Need for Caution in Low-Resource Settings.氯喹和羟氯喹在2019冠状病毒病中的应用：资源匮乏地区面临的挑战及谨慎使用的必要性
J Coll Physicians Surg Pak. 2020 Jun;30(6):78. doi: 10.29271/jcpsp.2020.Supp1.S78.
9
Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.羟氯喹作为新型冠状病毒肺炎暴露后预防用药
N Engl J Med. 2020 Sep 10;383(11):1087-1088. doi: 10.1056/NEJMc2023617. Epub 2020 Jul 15.
10
Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.羟氯喹作为新型冠状病毒肺炎暴露后预防用药
N Engl J Med. 2020 Sep 10;383(11):1088. doi: 10.1056/NEJMc2023617. Epub 2020 Jul 15.
引用本文的文献
1
Evidence in decision-making in the context of COVID-19 in Latin America.拉丁美洲新冠疫情背景下决策中的证据
Lancet Reg Health Am. 2022 Oct;14:100322. doi: 10.1016/j.lana.2022.100322. Epub 2022 Jul 20.
2
Efficacy of early treatment with hydroxychloroquine in people with mild to moderate COVID-19: a systematic review and meta-analysis.羟氯喹啉早期治疗对轻至中度新型冠状病毒肺炎患者的疗效：一项系统评价和荟萃分析。
Arch Med Sci. 2021 Oct 24;18(4):939-948. doi: 10.5114/aoms/143147. eCollection 2022.
3
Assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine using the CiPA concept.采用 CiPA 概念评估氯喹和羟氯喹的致心律失常风险。
Eur J Pharmacol. 2021 Dec 15;913:174632. doi: 10.1016/j.ejphar.2021.174632. Epub 2021 Nov 14.
4
The Emergency Use Authorization of Pharmaceuticals: History and Utility During the COVID-19 Pandemic.药品的紧急使用授权：在 COVID-19 大流行期间的历史和效用。
Pharmaceut Med. 2021 Jul;35(4):203-213. doi: 10.1007/s40290-021-00397-6. Epub 2021 Aug 28.
5
Characteristics, quality and volume of the first 5 months of the COVID-19 evidence synthesis infodemic: a meta-research study.COVID-19 证据合成信息疫情的前 5 个月的特征、质量和数量：一项元研究。
BMJ Evid Based Med. 2022 Jun;27(3):169-177. doi: 10.1136/bmjebm-2021-111710. Epub 2021 Jun 3.
6
QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.在接受羟氯喹、氯喹、阿奇霉素或洛匹那韦/利托那韦治疗的 COVID-19 患者中出现 QTc 延长：系统评价和荟萃分析。
Pharmacoepidemiol Drug Saf. 2021 Jun;30(6):694-706. doi: 10.1002/pds.5234. Epub 2021 Apr 3.
7
Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update.探讨羟氯喹在新冠病毒中的作用：一个有争议的药物的更新。
Food Chem Toxicol. 2021 May;151:112106. doi: 10.1016/j.fct.2021.112106. Epub 2021 Mar 15.
8
Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19.羟氯喹联合阿奇霉素治疗轻中度 COVID-19 住院患者。
Braz J Infect Dis. 2021 Mar-Apr;25(2):101549. doi: 10.1016/j.bjid.2021.101549. Epub 2021 Feb 19.
9
Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider.针对 SARS-CoV-2 感染的免疫调节疗法：一项系统文献综述，为 EULAR 考虑要点提供信息。
Ann Rheum Dis. 2021 Jun;80(6):803-815. doi: 10.1136/annrheumdis-2020-219725. Epub 2021 Feb 15.
10
Real-World Inpatient Use of Medications Repurposed for Coronavirus Disease 2019 in United States Hospitals, March-May 2020.2020年3月至5月美国医院中用于2019冠状病毒病的药物的真实世界住院使用情况
Open Forum Infect Dis. 2020 Dec 15;8(2):ofaa616. doi: 10.1093/ofid/ofaa616. eCollection 2021 Feb.
本文引用的文献
1
Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease.在患有轻至中度疾病的临床新冠肺炎患者中，羟氯喹与病毒清除较慢有关。
Medicine (Baltimore). 2020 Dec 24;99(52):e23720. doi: 10.1097/MD.0000000000023720.
2
A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19).一项多中心、随机、开放标签、对照试验，旨在评估羟氯喹的疗效和耐受性，以及一项针对轻症至中度 2019 冠状病毒病（COVID-19）成年患者的回顾性研究。
PLoS One. 2020 Dec 2;15(12):e0242763. doi: 10.1371/journal.pone.0242763. eCollection 2020.
3
Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19.羟氯喹在美国 COVID-19 住院患者中的使用效果。
Med. 2020 Dec 18;1(1):114-127.e3. doi: 10.1016/j.medj.2020.06.001. Epub 2020 Jun 5.
4
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.羟氯喹和托珠单抗治疗 COVID-19 患者：一项观察性研究。
PLoS One. 2020 Aug 13;15(8):e0237693. doi: 10.1371/journal.pone.0237693. eCollection 2020.
5
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.羟氯喹或联合阿奇霉素治疗轻中度 COVID-19。
N Engl J Med. 2020 Nov 19;383(21):2041-2052. doi: 10.1056/NEJMoa2019014. Epub 2020 Jul 23.
6
Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial.羟氯喹治疗轻症 2019 年冠状病毒病成人患者的随机对照临床试验。
Clin Infect Dis. 2021 Dec 6;73(11):e4073-e4081. doi: 10.1093/cid/ciaa1009.
7
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial.羟氯喹治疗非住院的 COVID-19 轻症成年患者：一项随机试验。
Ann Intern Med. 2020 Oct 20;173(8):623-631. doi: 10.7326/M20-4207. Epub 2020 Jul 16.
8
Update Alert: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.最新警报：羟氯喹啉或氯喹啉用于治疗或预防2019冠状病毒病
Ann Intern Med. 2020 Aug 18;173(4):W78-W79. doi: 10.7326/L20-0945. Epub 2020 Jul 15.
9
Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis.羟氯喹、洛匹那韦/利托那韦和标准治疗在重症 2019 冠状病毒病肺炎患者中的比较：一项机会性回顾性分析。
Crit Care. 2020 Jul 11;24(1):418. doi: 10.1186/s13054-020-03117-9.
10
Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.羟氯喹、阿奇霉素和联合治疗 COVID-19 住院患者。
Int J Infect Dis. 2020 Aug;97:396-403. doi: 10.1016/j.ijid.2020.06.099. Epub 2020 Jul 2.
Zotero 插件